Aeon Astron Europe B.V.

- Bio Cornea
- Drug Bonding and Embedding Technology
- Long Effective Injectable Dermal Filler
- Collagen Matrix & HA Matrix
- Life Science R&D

Eye tissue repair device to be introduced by Aeon Astron Europe B.V.

Aeon Astron Europe B.V., 4 September 2008, introduced it's ologen™ collagen matrix for eye tissue repair at the coming ESCRS 13-17 September 2008 in Berlin. The AAE (Aeon Astron Europe B.V.) booth number is 1623.

The ologen™ collagen matrix, previously called OculusGen, was first introduced to reduce subconjunctival and scleral scarring after trabeculectomy. Scarring at the external edge of the filtering bleb is the major cause of failure of glaucoma surgery. Scarring leads to increased when it is located either at the margins of the bleb or at the level of the scleral flap or its overlying episcleral connective tissue.

Trabeculectomy is not the only eye operation requiring cutting of the conjunctiva, and subconjunctival scarring is common after any of these operations. This unwanted scarring may lead to functional problems with vision, or eye movements in addition to failure of glaucoma filtering surgery.

The ologen™ collagen matrix mimics the extracellular matrix (ECM) and can induce regenerative tissue repair better than would wound modulation. By guiding the fibroblasts to grow randomly through the thousands of micropores within the ologen collagen implant, scar formation can be reduced. By this mechanism, the success rate for trabeculectomy is enhanced. This same repair mechanism can also play a substantial role in preventing scar formation for many ocular surgical procedures.

ologen™ collagen matrix not only modulates wound healing in the conjunctival space, it also creates a healthy and functional bleb and acts as a dynamic balance factor to prevent hypotony early after trabeculetomy.

Traditionally, surgeons have used MMC (mitomycin-C) to kill fibroblasts to inhibit fibrosis. However, MMC also kills normal cells. The ologen™ collagen implant guides, not kills, the cells, creating a physiological approach with proven efficacy and safety.

Aeon Astron Europe B.V.
Niels Bohrweg 11-13, 2333 CA Leiden,The Netherlands
Tel: +31 71 3322280 Fax: +31 71 3322281
Web: www.aeonastron.com, www.ologen.com Email: info@aeonastron.net

The application of ologen™ collagen matrix can be considered to modulate the wound for trabeculectomy, deep sclerotomy, glaucoma drainage device implantation, or other interventions that require conjunctival incisions that may lead to subconjunctival scarring. It can also inhibit wound contraction. The wound healing process, from the inflammatory phase to the end of the maturation and remodeling phase, may take as long as 6 months or more, depending on the wound size and closure. The ologen™ collagen matrix degrades in about three months and is helpful for the wound healing.

AAE's ologen™ collagen matrix uses atelocollagen, that can minimize the immune reaction. The new features and upgraded collagen matrix has many advantages than the previous one. Development of the new features commenced in early 2007 and the results appear much improved.

For more product information, please visit www.aeonastron.com or www.ologen.com for further information.

Aeon Astron Europe B.V.
Niels Bohrweg 11-13, 2333 CA Leiden, The Netherlands
Tel: + 31 71 3322280, Fax: +31 71 3322281
Email: praae@aeonastron.net
Web: www.ologen.com, www.aeonastron.com